L3VLUP
ProSign in

CRL · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CRLVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CRL
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCRLVRTX
Q3 202012 holders, $1.4bn31 holders, $21.9bn
Q4 202015 holders, $1.5bn30 holders, $18.4bn
Q1 202114 holders, $2.1bn31 holders, $15.4bn
Q2 202114 holders, $2.5bn30 holders, $12.7bn
Q3 202111 holders, $2.8bn35 holders, $10.1bn
Q4 202115 holders, $2.7bn28 holders, $12.4bn
Q1 202215 holders, $1.8bn23 holders, $16.1bn
Q2 202217 holders, $1.1bn25 holders, $18.1bn
Q3 202216 holders, $1.1bn22 holders, $18.4bn
Q4 202211 holders, $1.1bn28 holders, $18.4bn
Q1 20239 holders, $864m26 holders, $21.4bn
Q2 20239 holders, $755m27 holders, $24.7bn
Q3 202310 holders, $475m33 holders, $24.3bn
Q4 20239 holders, $536m32 holders, $28.6bn
Q1 20249 holders, $664m31 holders, $29.8bn
Q2 20247 holders, $385m29 holders, $33.4bn
Q3 20249 holders, $898m27 holders, $33.5bn
Q4 202410 holders, $1.0bn26 holders, $28.5bn
Q1 202512 holders, $1.0bn21 holders, $35.4bn
Q2 202515 holders, $1.3bn21 holders, $32.3bn
Q3 202511 holders, $1.2bn22 holders, $25.9bn
Q4 202516 holders, $2.1bn26 holders, $31.8bn
Q1 202614 holders, $2.7bn25 holders, $31.8bn
Q2 202612 holders, $3.7bn26 holders, $34.6bn
CRL

Charles Riv Labs Intl Inc

Holders
16
Reported value
$2.1bn
Buyers
19
Sellers
19

Breadth 0 among 92 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CRL (8)

D. E. Shaw & Co., Harris Associates LP, Moore Capital Management LP, PDT Partners LLC, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Walleye Capital LLC

Only VRTX (18)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →